COVID-19 Oral Antiviral Agents
Oral antiviral agents offer a new treatment option for nonhospitalized adult patients with COVID-19. Hear expert faculty discuss the safety and efficacy data of molnupiravir and nirmatrelvir (PF-07321332) plus ritonavir in outpatient adults with mild to moderate COVID-19.
Decera Clinical Education Infectious Disease Podcast · Renslow Sherer MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Renslow Sherer, MD, discusses key data on COVID-19 oral antiviral agents—molnupiravir and nirmatrelvir (PF-07321332) plus ritonavir—for nonhospitalized adults with mild to moderate COVID-19, including:
- EPIC-HR study of nirmatrelvir (PF-07321332) plus ritonavir
- Safety data
- Efficacy data
- MOVe-OUT study of molnupiravir
- Safety data
- Efficacy data
- Roles in treatment of COVID-19
- Timing of treatment
Presenter:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Review the downloadable slideset at:
https://bit.ly/31wi1Qi
Link to full program:
https://bit.ly/3EH2485
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.